Individualized medication testing project

Subdivision categories	Entry name	Methodology	Detection significance

Cardiovascular and cerebrovascular diseases	Personalized medication guidance for cardiovascular and cerebrovascular diseases 21 Genetic testing	Nucleic acid mass spectrometry	1. Analyze Drug metabolism ability, and guide clinicians to select appropriate drugs and doses; 2. Prediction of Adverse drug reaction to avoid or reduce drug harm; 3. Lifetime benefits from testing results, reducing unnecessary medical expenses.

Cardiovascular and cerebrovascular diseases	Cardiovascular and cerebrovascular personalized medicine guide 40 gene testing (Plus)	Nucleic acid mass spectrometry	The changes of drug metabolism, transport in vivo, genetic variation and expression level of target genes can lead to individual differences in drug response by affecting drug concentration and sensitivity in vivo. The detection of cardiovascular drug-related gene polymorphisms can guide the rational use of common drugs for cardiovascular diseases, and greatly improve the effectiveness and safety of cardiovascular drugs. Effectiveness: help to screen the appropriate drug variety and dose, improve drug efficiency, and provide the basis for multi-drug combination; Safety: reduce the risk of drug side effects and adverse reactions; Economy: reduce the pain and economic burden of patients, reduce doctor-patient conflicts and waste of medical resources.
Cardiovascular and cerebrovascular diseases	Individualized medication for hypertension guided genetic testing	Nucleic acid mass spectrometry	Guide the selection of medication and dosage for hypertension, and develop the most suitable antihypertensive plan; Guidance Selection β The best antihypertensive scheme of combination of receptor blocker, ARB, ACEI, Diuretic and CCB; Guiding individualized supplementation of folic acid in patients with H-type hypertension to reduce the risk of stroke.

Cardiovascular and cerebrovascular diseases	Individualized medication for hypertension guided genetic testing(Plus)	Nucleic acid mass spectrometry	To guide the selection of medication and dose of hypertension, and formulate the most suitable antihypertensive program; To guide the selection of the optimal antihypertensive regimen of β-blockers, ARB, ACEI, diuretics and CCB. To guide individual folic acid supplementation in patients with H-type hypertension to reduce the risk of stroke.
Cardiovascular and cerebrovascular diseases	Genetic testing of individualized antithrombotic drugs	Nucleic acid mass spectrometry	Personalized medication guidance will be given to patients taking Clopidogrel, Ticagrelor, aspirin, Cilostazol, Warfarin, Apixaban, and Dabigatran to improve the effectiveness of drug use and reduce the risk of adverse reactions.

Cardiovascular and cerebrovascular diseases	Genetic testing of individualized antithrombotic drugs(Plus)	Nucleic acid mass spectrometry	To guide the rational use of common antithrombotic drugs, reduce the risk of thrombosis or bleeding, achieve individualized drug treatment, and improve the effect of drug treatment for patients.
Cardiovascular and cerebrovascular diseases	Genetic testing guided by individualized medication for coronary heart disease	Nucleic acid mass spectrometry	Guide the rational use of 9 drugs, including antiplatelet, anti angina, and lipid-lowering drugs, predict medication risks and efficacy, and reduce toxic side effects.

Cardiovascular and cerebrovascular diseases	Genetic testing for individualized anticoagulant therapy	Nucleic acid mass spectrometry	To guide the rational use of three anticoagulants, including Rivaroxaban, Apixaban, and Dabigatran, to predict the risk and efficacy of drug use and reduce side effects.

Cardiovascular and cerebrovascular diseases	Gene detection of individualized medication for cerebral hemorrhage	Fluorescent PCR method	To guide the rational use of nimodipine, and to indicate the efficacy and the risk of adverse reactions.
Cardiovascular and cerebrovascular diseases	Genetic testing for individualized medicine of diabetes	Nucleic acid mass spectrometry	To guide the rational use of six hypoglycemic drugs, including Metformin, sulfonylurea Gliclazide, glipizide, glibenclamide, Glimepiride, and gliquidone, to predict the risk and efficacy of drug use and reduce toxic and side effects.

Cardiovascular and cerebrovascular diseases	Genetic testing for individualized medicine of diabetes(Plus)	Nucleic acid mass spectrometry	1. Reduce adverse reactions, avoid the risk of drug toxicity for patients, and increase drug safety; 2. Improve drug efficacy, effectively control blood glucose and reduce complications; 3. Shorten the testing cycle to avoid the waste of time and money caused by repeated testing; 4. Increase patient compliance.
Cardiovascular and cerebrovascular diseases	Genetic testing of personalized antiplatelet drugs	Nucleic acid mass spectrometry	To guide the rational use of Clopidogrel, aspirin, Ticagrelor, Cilostazol and other four drugs, predict the risk and efficacy of drug use, and reduce side effects.

Cardiovascular and cerebrovascular diseases	Genetic testing of personalized aspirin use	Fluorescence PCR method	Guide the rational use of aspirin in clinical practice, predict medication risks and efficacy, and reduce toxic side effects.
Cardiovascular and cerebrovascular diseases	Gene testing for personalized use of warfarin	Fluorescence PCR method	To guide the rational use of Warfarin, Coumarin anticoagulants, celecoxib, losartan, etc., predict the risk and efficacy of drug use, and reduce toxic and side effects.
Cardiovascular and cerebrovascular diseases	Genetic testing of Clopidogrel personalized drug use	Fluorescence PCR method	Guide the rational use of Clopidogrel, Omeprazole, etc., prevent thrombosis or bleeding, and reduce toxic and side effects.
Cardiovascular and cerebrovascular diseases	Genetic testing for individualized medication of antianginal drugs	Fluorescence PCR method	Guide the rational use of Nitroglycerin to avoid ineffective first aid; Guide healthy (reasonable) drinking to reduce harm to the body.
Cardiovascular and cerebrovascular diseases	Genetic testing for individualized treatment of hyperhomocysteinemia	Fluorescence PCR method	To prevent H-type hypertension and reduce the risk of stroke in patients with H-type hypertension.
Cardiovascular and cerebrovascular diseases	Genetic testing of individualized medicine for hyperlipidemia	Fluorescence PCR method	Guide the rational use of statin based lipid-lowering drugs, predict medication risks and efficacy, and reduce toxic side effects.
Cardiovascular and cerebrovascular diseases	Genetic testing of individualized medicine for hyperlipidemia(Plus)	Fluorescence PCR method	These results suggest the efficacy of lipid-lowering drugs and the risk of statin-induced myopathy.
Mental	Personalized medication for schizophrenia 10 Genetic testing	Nucleic acid mass spectrometry	By detecting genes related to 26 therapeutic drugs for schizophrenia, clinicians can be guided to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm.

Mental	Individualized medication for anxiety disorder 9 Genetic testing	Nucleic acid mass spectrometry	By detecting genes related to 17 therapeutic drugs for anxiety disorder, clinicians can be guided to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm.

Mental	Individualized medication for depression 10 Genetic testing	Nucleic acid mass spectrometry	By detecting genes related to 27 therapeutic drugs for depression, clinicians can be guided to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm.

Mental	Individualized medication for epilepsy 15 Genetic testing	Nucleic acid mass spectrometry	To guide clinicians to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm by detecting genes related to 16 therapeutic drugs for epilepsy.

Mental	Individualized use of sedative and hypnotic drugs 14 Genetic testing	Nucleic acid mass spectrometry	By detecting the genes related to 17 kinds of sedative and hypnotic drugs, clinicians can be guided to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm.

Mental	Personalized use of psychotropic drugs 14 Genetic testing	Nucleic acid mass spectrometry	By detecting genes related to 41 therapeutic drugs for depression, schizophrenia, anxiety and epilepsy, clinicians are instructed to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm.

Mental	Genetic testing of personalized medication 4 in attention deficit hyperactivity disorder	Nucleic acid mass spectrometry	To guide clinicians to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm by detecting genes related to three therapeutic drugs for attention deficit hyperactivity disorder.

Mental	Genetic testing of Individualized Medication 3 in Alzheimer's Disease	Nucleic acid mass spectrometry	To guide clinicians to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm by detecting genes related to four therapeutic drugs for Alzheimer's disease.

Digestive tract	Genetic testing of proton pump inhibitor related drugs	Fluorescence PCR method	Evaluate the clinical rational use of PPIs drugs, and indicate the dosage of drug use for different genotype populations.
Gout	Detection of Allopurinol related Genetic testing	Fluorescence PCR method	Assess the risk of SJS in patients who use allopurinol, and use it with caution or without caution in positive patients.
Gout	Detection of Allopurinol related Genetic testing(Plus)	Nucleic acid mass spectrometry	Appropriate ventilation drugs and doses should be selected to reduce adverse reactions and improve the therapeutic effect.
Immunosuppressant	Risk assessment of common immunosuppressive drugs	Nucleic acid mass spectrometry	Guide the selection of 10 Immunosuppressive drug drugs (Tacrolimus, sirolimus, Ciclosporin A, Azathioprine, 6-mercaptopurine, Tioguanine, prednisone, Prednisolone, methyl Prednisolone, methotrexate), Assist patients in selecting reasonable drug doses and reducing adverse reactions.

Bronchial class	Genetic testing of individualized drug use in asthma	Nucleic acid mass spectrometry	By detecting and interacting with glucocorticoids β 2 Receptor agonists, Leukotriene receptor antagonists and other genes related to commonly used therapeutic drugs for asthma, guide clinicians to select appropriate drugs and doses, predict Adverse drug reaction, and avoid or reduce drug harm.

Bronchial class	Asthma risk and individualized drug use Genetic testing	Nucleic acid mass spectrometry	Screening for genetic risks of childhood asthma and guiding precise medication are of great significance for the prevention, diagnosis, and treatment of childhood asthma.

Hormones	Genetic testing for individualized glucocorticoid use (Plus)	Nucleic acid mass spectrometry	To predict the risk of glucocorticoid-induced osteonecrosis of the femoral head and to intervene in patients with susceptible genes by combining high-dose glucocorticoids with bisphosphonates such as etidronate or zoledronic acid, In order to avoid the destruction of bone cells by glucocorticoids, reduce the risk of patients' medication, and ensure the safety and effectiveness of patients' medication.